109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
高强度聚焦超声消融术与腹腔镜子宫肌瘤剔除术对子宫肌瘤患者卵巢功能的影响
Authors Wang M, Zhu Q, Guan H, Zhao J, Gu P, Tang L
Received 1 September 2025
Accepted for publication 30 October 2025
Published 7 November 2025 Volume 2025:17 Pages 4239—4245
DOI https://doi.org/10.2147/IJWH.S560728
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Vinay Kumar
Mei Wang,1 Qing Zhu,1 Huijuan Guan,1 Jiahui Zhao,1 Pinlang Gu,1 Lisha Tang1,2
1Reproductive Medical Center, Lianyungang Maternal and Child Health Hospital, Lianyungang, Jiangsu, People’s Republic of China; 2State Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Medical University, Chongqing, People’s Republic of China
Correspondence: Lisha Tang, Reproductive Medical Center, Lianyungang Maternal and Child Health Hospital, State Key Laboratory of Ultrasound in Medicine and Engineering, Lianyungang, Jiangsu Province, 222000, People’s Republic of China, Email 89zhaiyao@163.com
Purpose: To explore the value of high-intensity focused ultrasound (HIFU) ablation and laparoscopic myomectomy (LM) in the treatment of uterine fibroids.
Methods: One hundred and twenty patients with uterine fibroids admitted to our hospital from October 2020 to September 2022 and were conducted a randomized controlled trial and randomly assigned to two groups, with 60 cases each. The uterine fibroid surgery group is divided into LM group and HIFU ablation group. The healthy control group consisted of 60 cases. Ovarian function evaluations were conducted at four time points before surgery, 6 months after surgery, 1 year, and 2 years. The final follow-up assessment was conducted in September 2024. The ovarian function changes and complication in HIFU and LM groups were compared.
Results: The AMH levels and AFC counts of the HIFU group at 6 months after surgery were (2.39± 0.35) ng/mL and (6.85± 1.06), which were higher than those of the LM group (2.15± 0.27) ng/mL and (6.02± 0.87), respectively, with statistical differences (P< 0.05). The incidence of HIFU complications was lower than that of the LM group, with statistical differences (P< 0.05). Upon further statistical analysis of relevant indicators at 1 and 2 years post-surgery for the two surgical methods, no statistical differences were observed between AMH and AFC.
Conclusion: After HIFU ablation for uterine fibroids in women aged 35– 40, ovarian function was not significantly affected in the short term (6 months after surgery) and the long term (2 years after surgery). Compared to LM, HIFU ablation is more effective in treating uterine fibroids, reducing the impact on patients’ ovarian function with fewer complications, and improving their quality of life.
Keywords: high intensity focused ultrasound, laparoscopic myomectomy, uterine fibroids, anti-Mullerian hormone, ovarian function
1Reproductive Medical Center, Lianyungang Maternal and Child Health Hospital, Lianyungang, Jiangsu, People’s Republic of China; 2State Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Medical University, Chongqing, People’s Republic of China
Correspondence: Lisha Tang, Reproductive Medical Center, Lianyungang Maternal and Child Health Hospital, State Key Laboratory of Ultrasound in Medicine and Engineering, Lianyungang, Jiangsu Province, 222000, People’s Republic of China, Email 89zhaiyao@163.com
Purpose: To explore the value of high-intensity focused ultrasound (HIFU) ablation and laparoscopic myomectomy (LM) in the treatment of uterine fibroids.
Methods: One hundred and twenty patients with uterine fibroids admitted to our hospital from October 2020 to September 2022 and were conducted a randomized controlled trial and randomly assigned to two groups, with 60 cases each. The uterine fibroid surgery group is divided into LM group and HIFU ablation group. The healthy control group consisted of 60 cases. Ovarian function evaluations were conducted at four time points before surgery, 6 months after surgery, 1 year, and 2 years. The final follow-up assessment was conducted in September 2024. The ovarian function changes and complication in HIFU and LM groups were compared.
Results: The AMH levels and AFC counts of the HIFU group at 6 months after surgery were (2.39± 0.35) ng/mL and (6.85± 1.06), which were higher than those of the LM group (2.15± 0.27) ng/mL and (6.02± 0.87), respectively, with statistical differences (P< 0.05). The incidence of HIFU complications was lower than that of the LM group, with statistical differences (P< 0.05). Upon further statistical analysis of relevant indicators at 1 and 2 years post-surgery for the two surgical methods, no statistical differences were observed between AMH and AFC.
Conclusion: After HIFU ablation for uterine fibroids in women aged 35– 40, ovarian function was not significantly affected in the short term (6 months after surgery) and the long term (2 years after surgery). Compared to LM, HIFU ablation is more effective in treating uterine fibroids, reducing the impact on patients’ ovarian function with fewer complications, and improving their quality of life.
Keywords: high intensity focused ultrasound, laparoscopic myomectomy, uterine fibroids, anti-Mullerian hormone, ovarian function